Cellid (299660) Fundamentals 2026 — Revenue Analysis | SniperIQ
Cellid (299660) is a KR-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ₩30.2B, trading at ₩1025.00 on the KOE. This SniperIQ fundamentals page covers Cellid's valuation, profitability (net margin -103.7%), revenue (₩8.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Cellid's market cap?
Cellid (299660) has a market capitalization of approximately ₩30.2B, trading at ₩1025.00 on the KOE. Market cap moves with the live share price.
What is Cellid's P/E ratio?
Cellid's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Cellid?
Cellid runs a net profit margin of -103.7%, a gross margin of 11.7%, and an operating margin of -101.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Cellid generate?
Cellid reported revenue of ₩8.8B for fiscal year 2025, with net income of -₩12.1B and earnings per share (EPS) of -409.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Cellid pay a dividend?
Cellid does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Cellid financially healthy?
Cellid carries a debt-to-equity ratio of 0.41x and a current ratio of 0.66x, with a market beta of 0.63. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Cellid a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Cellid (299660) the key facts are: market cap ₩30.2B, revenue ₩8.8B, 52-week range 973-4760. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Cellid's full fundamentals live
Get Cellid's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.